ALK and cystic kidney disease: In response to acquired resistance to crizotinib, several more potent next generation ALK inhibitors have been developed and are now used in the clinical setting [21] Renal cysts have not been reported as a complication of these more specific ALK directed therapies indicating that cystogenesis may be driven by inhibition of other molecules targeted by crizotinib.